These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 7937345)

  • 21. Glucagon-like peptide-1 and islet lipolysis.
    Sörhede Winzell M; Ahrén B
    Horm Metab Res; 2004; 36(11-12):795-803. PubMed ID: 15655711
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structure-activity relationships of glucagon-like peptide-1(7-36)amide: insulinotropic activities in perfused rat pancreases, and receptor binding and cyclic AMP production in RINm5F cells.
    Watanabe Y; Kawai K; Ohashi S; Yokota C; Suzuki S; Yamashita K
    J Endocrinol; 1994 Jan; 140(1):45-52. PubMed ID: 8138751
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glucagonlike peptide I (7-37) actions on endocrine pancreas.
    Weir GC; Mojsov S; Hendrick GK; Habener JF
    Diabetes; 1989 Mar; 38(3):338-42. PubMed ID: 2645190
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exendin-(9-39) is an inverse agonist of the murine glucagon-like peptide-1 receptor: implications for basal intracellular cyclic adenosine 3',5'-monophosphate levels and beta-cell glucose competence.
    Serre V; Dolci W; Schaerer E; Scrocchi L; Drucker D; Efrat S; Thorens B
    Endocrinology; 1998 Nov; 139(11):4448-54. PubMed ID: 9794451
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression and functional activity of glucagon, glucagon-like peptide I, and glucose-dependent insulinotropic peptide receptors in rat pancreatic islet cells.
    Moens K; Heimberg H; Flamez D; Huypens P; Quartier E; Ling Z; Pipeleers D; Gremlich S; Thorens B; Schuit F
    Diabetes; 1996 Feb; 45(2):257-61. PubMed ID: 8549871
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Distribution of glucagon receptors on hormone-specific endocrine cells of rat pancreatic islets.
    Kieffer TJ; Heller RS; Unson CG; Weir GC; Habener JF
    Endocrinology; 1996 Nov; 137(11):5119-25. PubMed ID: 8895386
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multisite regulation of insulin secretion by cAMP-increasing agonists: evidence that glucagon-like peptide 1 and glucagon act via distinct receptors.
    Gromada J; Ding WG; Barg S; Renström E; Rorsman P
    Pflugers Arch; 1997 Sep; 434(5):515-24. PubMed ID: 9242714
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evidence that glucagon stimulates insulin secretion through its own receptor in rats.
    Kawai K; Yokota C; Ohashi S; Watanabe Y; Yamashita K
    Diabetologia; 1995 Mar; 38(3):274-6. PubMed ID: 7758872
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transfection of pancreatic-derived beta-cells with a minigene encoding for human glucagon-like peptide-1 regulates glucose-dependent insulin synthesis and secretion.
    Hui H; Yu R; Bousquet C; Perfetti R
    Endocrinology; 2002 Sep; 143(9):3529-39. PubMed ID: 12193567
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of the role of N-glycosylation in cell-surface expression and binding properties of angiotensin II type-2 receptor of rat pheochromocytoma cells.
    Servant G; Dudley DT; Escher E; Guillemette G
    Biochem J; 1996 Jan; 313 ( Pt 1)(Pt 1):297-304. PubMed ID: 8546698
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interaction of GLP-I and leptin at rat pancreatic B-cells: effects on insulin secretion and signal transduction.
    Fehmann HC; Bode HP; Ebert T; Karl A; Göke B
    Horm Metab Res; 1997 Nov; 29(11):572-6. PubMed ID: 9479558
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.
    Holst JJ
    Expert Opin Emerg Drugs; 2004 May; 9(1):155-66. PubMed ID: 15155141
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The multifaceted potential of glucagon-like peptide-1 as a therapeutic agent.
    Lam NT; Kieffer TJ
    Minerva Endocrinol; 2002 Jun; 27(2):79-93. PubMed ID: 11961501
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Insulinotropic glucagon-like peptide I receptor expression in glucagon-producing alpha-cells of the rat endocrine pancreas.
    Heller RS; Kieffer TJ; Habener JF
    Diabetes; 1997 May; 46(5):785-91. PubMed ID: 9133545
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term insulinotropic activity of glucagon-like peptide-1/polymer conjugate on islet microcapsules.
    Kim S; Bae YH
    Tissue Eng; 2004; 10(11-12):1607-16. PubMed ID: 15684669
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of glucagonlike peptide I-(7-36) on release of insulin, glucagon, and somatostatin by rat pancreatic islet cell monolayer cultures.
    D'Alessio DA; Fujimoto WY; Ensinck JW
    Diabetes; 1989 Dec; 38(12):1534-8. PubMed ID: 2573553
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glucagon-like peptide-1 structure, function and potential use for NIDDM.
    Gefel D; Barg Y; Zimlichman R
    Isr J Med Sci; 1997 Oct; 33(10):690-5. PubMed ID: 9397146
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pancreatic beta-cells expressing GLP-1 are resistant to the toxic effects of immunosuppressive drugs.
    D'Amico E; Hui H; Khoury N; Di Mario U; Perfetti R
    J Mol Endocrinol; 2005 Apr; 34(2):377-90. PubMed ID: 15821104
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Basal receptor activation by locally produced glucagon-like peptide-1 contributes to maintaining beta-cell function.
    Masur K; Tibaduiza EC; Chen C; Ligon B; Beinborn M
    Mol Endocrinol; 2005 May; 19(5):1373-82. PubMed ID: 15677711
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets.
    Farilla L; Bulotta A; Hirshberg B; Li Calzi S; Khoury N; Noushmehr H; Bertolotto C; Di Mario U; Harlan DM; Perfetti R
    Endocrinology; 2003 Dec; 144(12):5149-58. PubMed ID: 12960095
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.